The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927).
Dawn L. Hershman
No relevant relationships to disclose
Joseph M. Unger
No relevant relationships to disclose
Katherine D. Crew
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Danielle Awad
No relevant relationships to disclose
Heather Greenlee
No relevant relationships to disclose
Lori M. Minasian
No relevant relationships to disclose
Lisa Hansen
No relevant relationships to disclose
Danika Lew
No relevant relationships to disclose
Julie Gralow
Research Funding - Amgen; Novartis; Roche
James Lloyd Wade
No relevant relationships to disclose
Frank L. Meyskens
No relevant relationships to disclose
Carol Moinpour
No relevant relationships to disclose